- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | Sage wilts as Huntington's prospect flunks trial | ||
| Mi | Pfizer bags EU okay for haemophilia drug Hympavzi | ||
| Mi | Trump picks celebrity doc Mehmet Oz to lead Medicare | ||
| Mi | NICE blames companies for breakdown in Enhertu talks | ||
| Mi | MSD says subcutaneous Keytruda matches IV form | ||
| Di | NIH algorithm matches patients to clinical trials | ||
| Di | GSK drug raises hopes for patients with PBC itch | ||
| Di | J&J plots filings after psoriasis drug clears phase 3 test | ||
| Di | FDA says no to Astellas' geographic atrophy drug | ||
| Di | Grifols linked to €7bn takeover offer from Brookfield | ||
| Mo | Neurogene falls again on Rett gene therapy side effects | ||
| Mo | AI could 'cut ECG result wait times and speed up treatment' | ||
| Mo | AbbVie bags EU nod for key drug from ImmunoGen takeover | ||
| Mo | Tirzepatide gets a big win in obesity-related heart failure | ||
| Mo | Syndax gets FDA okay for first-in-class leukaemia drug | ||
| Fr | Trump pick of RFK for top US health job astounds critics | ||
| 14.11. | MSD joins PD-1/VEGF push in cancer with LaNova deal | ||
| 14.11. | Syncona aims Slingshot at biotech's 'translational gap' | ||
| 14.11. | GSK hails survival data with revived myeloma drug Blenrep | ||
| 14.11. | Metsera gets $215m for obesity trials, and other financings | ||
| 14.11. | PTC gets FDA okay for first brain-delivered gene therapy | ||
| 13.11. | Amgen plays down safety concern with obesity candidate | ||
| 13.11. | BioNTech buys Biotheus and its Keytruda rival for $950m | ||
| 13.11. | Sanofi wins appeal in spat with NICE over Sarclisa | ||
| 13.11. | Ali Parsa is back in digital health with start-up Quadrivia |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
